| Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | Irritability Associated With Autism Spectrum Disorder | Recruiting | Phase 3 | 2026-09-25 | | NCT06706674 |
|---|
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-25 | | NCT06559306 |
|---|
| Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Bipolar and Related Disorders, bipolar disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-25 | | NCT06372964 |
|---|
| Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder | Bipolar and Related Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, autism spectrum disorder, bipolar disorder, mood disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-25 | | NCT06229210 |
|---|
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-25 | | NCT05850689 |
|---|
| Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder | Bipolar I or II Disorder | Active, not recruiting | Phase 2 | 2026-09-23 | | NCT07220460 |
|---|
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | bipolar I disorder, depressive disorder | Recruiting | Phase 3 | 2026-07-27 | | NCT04777357 |
|---|
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-07-24 | | NCT06966401 |
|---|
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-06-17 | | NCT06846320 |
|---|
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-06-15 | | NCT07276997 |
|---|
| Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2025-10-29 | | NCT06786624 |
|---|